Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Prior dengue infection may protect against Zika: study

Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.

Read More »

Takeda dengue vaccine meets main study goal of trial

Takeda Pharmaceutical’s experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of a late-stage clinical trial.

Read More »

Sanofi pins hopes on new drugs after setbacks

Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.

Read More »

Philippines to seek refund of $59 million from Sanofi amid vaccine risk

The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.

Read More »

Philippines halts sale of dengue vaccine as Sanofi downplays riskd

The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country.

Read More »

Philippines orders probe into Sanofi dengue vaccine for 730,000 children

The Philippines ordered a probe on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by the French drug company Sanofi that it could worsen the disease in some cases.

Read More »

Sanofi ends development of C. difficile vaccine

Sanofi SA ended development of an experimental vaccine for Clostridium difficile infection.

Read More »

Sanofi expects $120 million hit as dengue vaccine hits major snag

Use of Sanofi’s dengue vaccine, the world’s first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection.

Read More »

Takeda moves ahead in Zika race with launch of vaccine trial

Japan’s Takeda Pharmaceutical moved ahead in the race to develop a vaccine for the mosquito-borne Zika virus, with the start of a clinical trial program backed by the U.S. government.

Read More »

Takeda to develop Zika vaccine with U.S. funding

Japanese drugmaker Takeda Pharmaceutical Co. said it is developing a vaccine to prevent the Zika virus, which has been linked to severe birth defects, and has secured funding from a U.S. government agency.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom